Journal
BIOMARKERS IN MEDICINE
Volume 4, Issue 1, Pages 91-98Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/BMM.09.80
Keywords
Alzheimer's disease; amyloid; biomarkers; cerebrospinal fluid; clinical trials; plasma; tau
Categories
Funding
- Royal Swedish Academy of Sciences
- Swedish Research Council
- Alzheimer's Association
- NIH [U01-AG024904]
Ask authors/readers for more resources
This article summarizes how biochemical markers may aid in the development of novel treatments that interfere with fundamental pathogenic processes in Alzheimer's disease. Details are given on the potential use of biomarkers in Alzheimer's disease clinical trials as additional inclusion criteria to enrich study populations with participants who really suffer from the disease, as a means to stratify study participants into meaningful subgroups that may benefit differently from the treatment, and as tools to detect desired biochemical effects and undesired side effects of the drug.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available